Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2022; 14(9): 1718-1729
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1718
Therapies for non-alcoholic fatty liver disease: A 2022 update
Katie Shen, Achintya D Singh, Jamak Modaresi Esfeh, Jamile Wakim-Fleming
Katie Shen, Achintya D Singh, Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Jamak Modaresi Esfeh, Jamile Wakim-Fleming, Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Author contributions: Shen K and Singh AD contributed to paper design, primary analysis, manuscript writing; Shen K contributed to literature review; Modaresi Esfeh J and Wakim-Fleming F contributed to critical revisions; all authors have made a significant contribution to this study and have approved the final manuscript.
Conflict-of-interest statement: There are no conflicts of interest or supportive foundations to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Katie Shen, MD, Doctor, Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, United States. shenk2@ccf.org
Received: May 19, 2022
Peer-review started: May 19, 2022
First decision: June 9, 2022
Revised: June 22, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 27, 2022
Processing time: 126 Days and 7.6 Hours
Core Tip

Core Tip: Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing epidemic with high morbidity and mortality. Although lifestyle modifications will remain a cornerstone of disease management, a multitude of therapies are under development that target different aspects of NAFLD pathogenesis.